About-cancer/treatment/drugs/caplacizumab-yhdp/zh

卡帕珠单抗

本页包含有关caplacizumab-yhdp的简要信息，以及一些链接，这些链接指向有关该药物的用途，研究结果和正在进行的临床试验的更多信息。

美国品牌名称

卡布利维

FDA批准

是

该药物的FDA标签信息可从DailyMed获得。

用于癌症

Caplacizumab-yhdp被批准用于治疗：

• 获得性血栓性血小板减少性紫癜 （aTTP）在成人中。 它与血浆置换和免疫抑制疗法一起使用。

有关Caplacizumab-yhdp的更多信息

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Clinical Trials Accepting Patients

Find Clinical Trials for Caplacizumab-yhdp - Check for trials from NCI's list of cancer clinical trials now accepting patients.

Important: The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.